New Notices
- New Notice of Intent to Revise: Desvenlafaxine Succinate (posted 30-Aug-2024)
- New Notice of Intent to Revise: Xylazine (posted 30-Aug-2024)
- New Notice of Intent to Revise: Xylazine Hydrochloride (posted 30-Aug-2024)
- New Notice of Intent to Revise: Xylazine Injection (posted 30-Aug-2024)
- New General Chapter Prospectus: <320> NMR Spectroscopy for Determination of Degree of Hydrolysis for Polyvinyl Alcohol and Vinyl Alcohol Homopolymer, and Monomer Ratio for Vinyl Alcohol and Vinyl Acetate Copolymer (posted 30-Aug-2024; input deadline 29-Sep-2024)
- New General Announcement: Analytical Procedures for Quality of mRNA Vaccines and Therapeutics (Draft Guidelines: 3rd Edition) (posted 02-Aug-2024; input deadline 31-Oct-2024)
- New Notice of Intent to Revise: Sodium Polystyrene Sulfonate Suspension (posted 26-Jul-2024)
- New Pending Revision Notice: Guanfacine Extended-Release Tablets (posted 28-Jun-2024)
- New Notice of Intent to Revise: GC <731> Loss on Drying (posted 28-Jun-2024)
- New Notice of Intent to Revise: Cranberry Fruit Juice Dry Extract (posted 28-Jun-2024)
- New Notices of Intent to Revise: Rufinamide (posted 28-Jun-2024)
- New Notice of Intent to Revise: Teriparatide Injection (posted 28-Jun-2024)
- New Notice of Intent to Revise: Polyethylene Glycol Castor Oil (posted 13-Jun-2024, input deadline 15-Jul-2024)
- New Publication Notice: USP-NF Online: Retirement of PDFs (posted 28-Jun-2024) En español
- New Pending Revision Notice: Haloperidol Tablets (posted 31-May-2024
- New Pending Revision Notice: Paroxetine Extended-Release Tablets (posted 31-May-2024)
- New Notice of Intent to Revise: Magnesium Sulfate (posted 31-May-2024)
- New General Chapter Prospectus:<1157> USP-Listed Device Monographs and Recommendations for Product Quality and Performance Testing of the Drug Component of Combination Products (posted 31-May-2024)
- New Notice of Intent to Revise: Norflurane (posted 10-May-2024)